Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: A single-center study

Urology

Volumn 61, Issue 2, 2003, Pages 338-341

  Berger, Andreas P ^a   Steiner, Hannes ^a   Stenzl, Arnulf ^a   Akkad, Thomas ^a   Bartsch, Georg ^a   Holtl, Lorenz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

ADULT; AGED; ARTICLE; BLADDER CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; LASER; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RECURRENT CANCER; SKIN MANIFESTATION; SUPERFICIAL CANCER; URINARY TRACT INFECTION;

EID: 0037321044     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02123-4     Document Type: Article

References (15)

1. Kelly J.F., Snell M.E., Berenbaum M.C. Photodynamic destruction of human bladder carcinoma. Br J Cancer. 31:1975;237-244.
2. Moan J., Berg K. Photochemotherapy of cancer experimental research . Photochem Photobiol. 55:1992;931-948.
3. Bachor R., Reich E., Rueck A., et al. Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells. Urol Res. 24:1996;285-289.
4. Wolf P., Kerl H. Photodynamic therapy in patients with xeroderma pigmentosum. Lancet. 337:1991;1613-1614.
5. Svanberg K., Andersson T., Killander D., et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino-levulinic acid sensitization and laser irradiation. Br J Dermatol. 130:1994;743-751.
6. Kriegmair M., Baumgartner R., Lumper W., et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol. 77:1996;667-671.
7. Waidelich R., Stepp H., Baumgartner R., et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancers. J Urol. 165:2001;1904-1907.
8. Datta S.N., Allman R., Loh C.S., et al. Photodynamic therapy of bladder cancer cell lines. Br J Urol. 80:1997;421-426.
9. Waidelich R., Hofstetter A., Stepp H., et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol. 159:1998;401-404.
10. Prout G.R., Lin C.W., Benson R., et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med. 317:1987;1251-1255.
11. Nseyo U.O., Dougherty T.J., Boyle D.G., et al. Whole bladder photodynamic therapy for transitional cell carcinoma of the bladder. Urology. 26:1985;274-280.
12. Steinbach P., Kriegmair M., Baumgartner R., et al. Intravesical instillation of 5-aminolevulinic acid the fluorescent metabolite is limited to urothelial cells . Urology. 44:1994;676-681.
13. Smith J.A., Labasky R.F., Cockett A.T.K., et al. Bladder Cancer Clinical Guidelines Panel Summary Report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol. 162:1999;1697-1701.
14. Bassi P.F. BCG (bacillus of Calmette Guérin) therapy of high-risk superficial bladder cancer. Surg Oncol. 11:2002;77-83.
15. Catalona W., Hudson M.A., Gillen D.P., et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol. 137:1987;220-224.